Ph. Eur. General Notices Chapter - New Structure and Content
Recommendation

19/20 May 2026
All relevant GMP/GACP aspects for Medical Cannabis
The European Pharmacopoeia (Ph. Eur.) Commission adopted a revised version of Ph. Eur. chapter 1. General Notices to provide greater clarity for users.
New structure and content
The revised Ph. Eur. chapter 1 General Notices features new additions such as
- a section on monographs for medicinal products containing chemically defined APIs. This new section also provides information on related substances and impurities.
- a sub-section on “Demonstration of suitability of monographs”.
- a single section concerning monographs on herbal drugs, containing all paragraphs that were previously dispersed throughout the text.
- an explanation of the rounding rule, information on chiral substances and an example of equivalents (in the tests and assay sections).
-
a clarification of the scope of first and second identification series and of alternative identifications.
In addition, the wording and terminology have been further harmonized. For example,
- “medicinal product” is selected instead of “finished product” and “pharmaceutical preparation”.
- “shelf life” and “re-test period” will be used instead of “period of use” and “period of validity”.
The revised Ph. Eur. chapter 1 General Notices will be published in Ph. Eur. Supplement 10.7, available in October 2021 (implementation date: 1 April 2022).
More information can be found in the EDQM Newsroom: Adoption of the revised General Notices chapter.
Related GMP News
15.04.2026ICH Q9 Training Package updated
01.04.2026New EMA GMP Guidelines in the next three Years
01.04.2026New EMA Guidance: Risk Management for Elemental Impurities in Veterinary Medicinal Products
18.03.2026Sampling in the Focus of the FDA
11.03.2026EU Pharma Package: Final Texts officially published
11.03.2026FDA Guidance Plans for 2026


